Cancer Antigen CA125 Human ELISA Kit (ab108653)
- Product nameCancer Antigen CA125 Human ELISA Kit
- Detection methodColorimetric
- Tests1 x 96 well plate
- Sample typeSerum
- Assay typeSandwich (quantitative)
- Sensitivity= 5 U/ml
- Range5 U/ml - 400 U/ml
- Assay durationMultiple steps standard assay
- Species reactivityReacts with: Human
- Product overview
ab108653 is for the quantitative determination of the Cancer Antigen CA125 concentration in human serum.
Cancer Antigen 125 (CA125) is a surface antigen associated with epithelial ovarian cancer. In serum, CA125 is associated with a high molecular weight glycoprotein. Published studies have indicated that elevated serum CA125 levels can be found in individuals with serious endometroid, clear-cell and undifferentiated ovarian carcinoma.
The serum CA125 concentration is greater than 35 units per ml in 60% of women with ovarian cancer and >80% of patients with disseminated ovarian cancer. The serum CA125 is elevated in 1% of normal healthy women, 3% of normal healthy women with benign ovarian diseases, and 6% of patients with non-neoplastic conditions (including but not limited to first trimester pregnancy, menstruation, endometriosis, uterine fibrosis, acute salphingitis, hepatic diseases and inflammation of peritoneum, pericardium or pleura). Serum CA125 concentration may be useful in monitoring treatment and distinguishing between good response to treatment and progressive malignant disease with poor therapeutic response. To date, CA125 is the most sensitive marker for residual epithelial ovarian cancer.
- Tested applicationsELISA more details
- Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests 20X Washing Solution 1 x 50ml CA125 reference standards containing; 0, 15, 50, 100, 200, and 400 Unit/ml of CA125 6 x 1ml Enzyme Conjugate Reagent 1 x 13ml Murine Monoclonal anti-CA125 coated microtiter plate 1 unit Stop Solution 1 x 11ml TMB Substrate Solution 1 x 11ml
- Research Areas
- FunctionThought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
- Tissue specificityExpressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas.
- Sequence similaritiesContains 2 ANK repeats.
Contains 56 SEA domains.
- DomainComposed of three domains, a Ser-, Thr-rich N-terminal domain, a repeated domain containing more than 60 partially conserved tandem repeats of 156 amino acids each (AAs 12061-21862) and a C-terminal transmembrane contain domain with a short cytoplasmic tail.
modificationsHeavily O-glycosylated; expresses both type 1 and type 2 core glycans.
Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans.
May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space.
May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts.
- Cellular localizationCell membrane. Secreted > extracellular space. May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.
- CA 125
- MUC 16
- Mucin 16
- Ovarian cancer related tumor marker CA125
- Ovarian cancer-related tumor marker CA125
- Ovarian carcinoma antigen CA125
Our Abpromise guarantee covers the use of ab108653 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
References for Cancer Antigen CA125 Human ELISA Kit (ab108653)
ab108653 has not yet been referenced specifically in any publications.